ONCOassist

Name: ONCOassist
Rating: 4.9 (115 reviews)
Author: Portable Medical Technology Ltd

By: Portable Medical Technology Ltd App

The go-to app in oncology

Overview

Version:

9.28.0

Last updated: 2026-08-05

Ranking

#125,197 ▼ 61

Overall

Features & Capabilities

ONCOassist is a comprehensive decision-support suite for oncology professionals, integrating NCCN treatment protocols, adjuvant survival estimates, prognostic scores, drug information, a drug interaction checker, CTCAE criteria, AJCC TNM staging, IO toxicity management, and access to ONCOnews and ONCOvideos. It supports offline use and includes 200+ oncology drugs and calculators among other decision-support tools.

ONCOassist saves time, supports evidence-based care, and is CE-marked and HPRA-regulated. It is intended for healthcare professionals and does not replace clinical judgement. Regular updates are driven by user feedback; contact feedback@oncoassist.com for input.

User Growth & Download Statistics

App AI Analytics Data Education Developer Tools

By:

Portable Medical Technology Ltd

Rating:

4.90

(115)

Version:

9.28.0 Last updated: 2026-08-05

Version code:

889243362

Creation date:

2017-08-09

Compatible devices:

Size:

240.52MB

URLs:

Website ,Privacy policy

Full description:

Source:

Apple Apps Store

Data ingested on:

2026-08-07

Compare stats and ranking:

Ranking

# 125,197 ▼ 61

Other platforms

ONCOassist (v9.28.0)

94,569 4.70

(684)

For Developers

Monetize with App Pass Boost with Extension Booster

Contact the developer

Chrome-Stats does not own this Apple app. Please use these information below to contact the Apple app developer.

Developed by:

Portable Medical Technology Ltd

Apple Apps Store

https://apps.apple.com/us/app/oncoassist/id558299114

Website:

http://oncoassist.com/

User Reviews

Reviewers consistently praise ONCOassist for current, reliable oncology data and a broad, integrated toolkit. The CTCAE search feature, ease of use, and quick access make it a go-to resource for clinical practice and research, including prognosis discussions, risk assessment, RECIST, and trial planning. Overall, it's viewed as essential and continually improved by oncology providers.

Pros